Prevalence and laboratory-associated variability of non-criteria antiphospholipid antibodies in women with pregnancy loss: A cross-sectional study.
- 1Department of Reproductive Medicine, Lanzhou University Second Hospital, Lanzhou, 730030, China.
- 2Department of Obstetrics and Gynecology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Abstract
Background
Non-criteria antiphospholipid antibodies (NC-aPLs) may supplement criteria antiphospholipid antibody testing in women with pregnancy loss, but their prevalence, laboratory-associated variability, and susceptibility to pregnancy status remain incompletely characterized.Methods
This cross-sectional study included 1897 women with a history of pregnancy loss who underwent testing for 10 NC-aPLs at three independent commercial laboratories. Positivity was defined using laboratory-specific manufacturer reference ranges. We compared positivity across laboratories and by criteria aPL status, pregnancy status at testing, and number of previous losses. Multivariable logistic regression evaluated associations between pregnancy status and individual NC-aPL positivity.Results
Overall, 55.5% of women had at least one positive NC-aPL; 54.6% of those negative for criteria aPLs remained positive for at least one NC-aPL. Positivity differed across laboratories for 8 of 10 markers, with marked variation for aAnxA5-IgG (8.6%-29.8%) and aPE-IgG (4.8%-24.3%). After adjustment, pregnancy at testing was associated with higher odds of aAnxA5-IgG positivity, whereas no significant associations were observed for the other nine markers. NC-aPL positivity showed no significant trend with the number of previous pregnancy losses.Conclusions
NC-aPLs were common in women with pregnancy loss, including those negative for criteria aPLs. Substantial laboratory-associated variability highlights a barrier to clinical interpretation and the need for assay standardization. The association between pregnancy status and aAnxA5-IgG positivity warrants longitudinal evaluation.
Related
- CO102 | VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODY TESTING AND TREATMENT STRATEGIES IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: RESULTS FROM THE OAPS-CARE SURVEY, ON BEHALF OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES
- Anticoagulation Monitoring in Recurrent Venous Thromboembolism Associated With Antiphospholipid Antibodies and Subsequent Heparin-Induced Thrombocytopenia.
- Prevalence and factors associated with hepatitis B surface antibody seroprotection among healthcare workers undergoing laboratory testing at Eastgate Clinic, Windhoek, Namibia: A retrospective cross-sectional study
- PO067 | LONG‑TERM SAFETY AND EFFECTIVENESS OF VITAMIN K ANTAGONISTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES: A RETROSPECTIVE COHORT ANALYSIS
- CO100 | ANTIPHOSPHATIDYLSERINE–PROTHROMBIN ANTIBODIES IN ANTIPHOSPHOLIPID SYNDROME: CLINICAL ASSOCIATIONS AND DIAGNOSTIC GAPS MAPPED BY A SCOPING REVIEW
BibTeX
@article{ding2026prevalence,
title = {{Prevalence and laboratory-associated variability of non-criteria antiphospholipid antibodies in women with pregnancy loss: A cross-sectional study.}},
author = {Nan Ding and Ruifang Wang and Kexin Wang and Guosheng Li and Fang Wang},
journal = {Journal of translational autoimmunity},
year = {2026},
month = oct,
doi = {10.1016/j.jtauto.2026.100408},
url = {https://europepmc.org/article/MED/42921379},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Prevalence and laboratory-associated variability of non-criteria antiphospholipid antibodies in women with pregnancy loss: A cross-sectional study.
AU - Nan Ding
AU - Ruifang Wang
AU - Kexin Wang
AU - Guosheng Li
AU - Fang Wang
PY - 2026
DA - 2026/10/08
JO - Journal of translational autoimmunity
DO - 10.1016/j.jtauto.2026.100408
UR - https://europepmc.org/article/MED/42921379
AB - Background Non-criteria antiphospholipid antibodies (NC-aPLs) may supplement criteria antiphospholipid antibody testing in women with pregnancy loss, but their prevalence, laboratory-associated variability, and susceptibility to pregnancy status remain incompletely characterized.Methods This cross-sectional study included 1897 women with a history of pregnancy loss who underwent testing for 10 NC-aPLs at three independent commercial laboratories. Positivity was defined using laboratory-specific manufacturer reference ranges. We compared positivity across laboratories and by criteria aPL status, pregnancy status at testing, and number of previous losses. Multivariable logistic regression evaluated associations between pregnancy status and individual NC-aPL positivity.Results Overall, 55.5% of women had at least one positive NC-aPL; 54.6% of those negative for criteria aPLs remained positive for at least one NC-aPL. Positivity differed across laboratories for 8 of 10 markers, with marked variation for aAnxA5-IgG (8.6%-29.8%) and aPE-IgG (4.8%-24.3%). After adjustment, pregnancy at testing was associated with higher odds of aAnxA5-IgG positivity, whereas no significant associations were observed for the other nine markers. NC-aPL positivity showed no significant trend with the number of previous pregnancy losses.Conclusions NC-aPLs were common in women with pregnancy loss, including those negative for criteria aPLs. Substantial laboratory-associated variability highlights a barrier to clinical interpretation and the need for assay standardization. The association between pregnancy status and aAnxA5-IgG positivity warrants longitudinal evaluation.
SN - 2589-9090
ER -